These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20934891)

  • 21. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
    Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
    J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
    Deegan PB; Moran MT; McFarlane I; Schofield JP; Boot RG; Aerts JM; Cox TM
    Blood Cells Mol Dis; 2005; 35(2):259-67. PubMed ID: 16125420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
    Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
    Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
    Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H; Kaplan P; Kacena K; Yee J
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI; Giraldo P; Giralt M
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
    Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.